Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1868 Target Snapshot

Vascular endothelial growth factor receptor 1 · SINGLE PROTEIN · Homo sapiens

4,539Compounds
814Assays
37Approved Drugs
4,504.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Vascular endothelial growth factor receptor 1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P17948. Start with cancer, then reuse UniProt P17948 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P17948 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
cancer

Vascular endothelial growth factor receptor 1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include AEE-788, FAMITINIB, SUNITINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vascular endothelial growth factor receptor 1 as ChEMBL target CHEMBL1868, mapped to UniProt P17948. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Vascular endothelial growth factor receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1868
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P17948
Vascular endothelial growth factor receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Vascular endothelial growth factor receptor 1 is the right protein anchor across sources, using UniProt P17948 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVascular endothelial growth factor receptor 1
UniProt AccessionP17948
Component TypeProtein
Sequence Length1338 aa

Vascular endothelial growth factor receptor 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Vascular endothelial growth factor receptor 1, mapped to UniProt P17948. Sequence length is 1338 aa.

Mapped IDP17948
Review nameVascular endothelial growth factor receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Vascular endothelial growth factor receptor 1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugAEE-788
Linked drugFAMITINIB
Linked drugSUNITINIB
Approved-linked Approved
neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugFAMITINIB
Linked drugICRUCUMAB
Linked drugSUNITINIB
Approved-linked Approved
gastrointestinal stromal tumor
2 linked drugs · 2 direct · 2 efficacy
Linked drugFAMITINIB
Linked drugSUNITINIB
Approved-linked Approved
renal cell carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugFAMITINIB
Linked drugSUNITINIB
Approved-linked Approved
clear cell renal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSUNITINIB
Approved-linked Approved
neuroendocrine neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugSUNITINIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include AEE-788, FAMITINIB, SUNITINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

37
Approved
26
Phase III
28
Phase II
17
Phase I
Assay Mix

Activity Type Distribution

IC502,491.0
KI1,849.0
EC5034.0
KD130.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL272938 10.3 Ki 0.05012 Preclinical
CHEMBL1986979 10.2 Ki 0.0631 Preclinical
CHEMBL374044 10.1 Ki 0.07943 Preclinical
CHEMBL1993996 10.0 Ki 0.1 Preclinical
CHEMBL3939307 10.0 IC50 0.1 Preclinical
CHEMBL1289926 10.0 IC50 0.1 Approved
CHEMBL1994638 9.9 Ki 0.1259 Preclinical
CHEMBL373798 9.8 Ki 0.1585 Preclinical
CHEMBL271441 9.8 Ki 0.1585 Preclinical
CHEMBL403402 9.7 Ki 0.1995 Preclinical
Distribution

pChEMBL Value Distribution

81
5.0
161
5.5
300
6.0
329
6.5
286
7.0
191
7.5
165
8.0
83
8.5
46
9.0
15
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
FRUQUINTINIB
CHEMBL4303214
Approved 2023
PEXIDARTINIB
CHEMBL3813873
Approved 2019
ENTRECTINIB
CHEMBL1983268
Approved 2019
TIVOZANIB
CHEMBL1289494
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
LENVATINIB
CHEMBL1289601
Approved 2015
NINTEDANIB
CHEMBL502835
Approved 2014
NINTEDANIB ESYLATE
CHEMBL3039504
Approved 2014
CABOZANTINIB
CHEMBL2105717
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

814
Total Assays
1,256
Tested Compounds
3
Assay Types
Binding — 805 assays, 1,256 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 661 1,019 6.8
cell-based format 84 176 6.4
assay format 54 61 6.4
organism-based format 6 0
ADME — 6 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 2 7.4
cell-based format 1 0
Functional — 3 assays, 341 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 341 7.1
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine